Manhattan Scientifics, Inc. Announces the Engagement of Loraine Upham to Market Its Cancer Diagnostic Technology
8/23/2013 9:29:16 AM
ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Manhattan Scientifics (OTCQB:MHTX) announced today that Loraine Upham has been engaged as a consultant to support its cancer team. The technology, developed by Edward R. Flynn, PhD, provides the most specific and most sensitive method for detecting cancer currently known. Ms. Upham’s role will be to identify initial markets and facilitate relationships with strategic partners for the company. Loraine Upham has over 30 years of biotechnology commercialization experience. She is best known for her co-invention and development of a novel treatment for diabetes that was partnered in a $335M deal with Sanofi-Aventis in 2010.
Help employers find you! Check out all the jobs and post your resume.
comments powered by